Latest Pharma Insights
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis
In an interview, Avere CEO Andrew Cheng pointed out that a potential advantage to AVR-001 versus J&J’s Icotyde is that Avere’s IL-23 antagonist can be dosed weekly instead of daily.
Scrip - July 14, 2026
In an interview, Avere CEO Andrew Cheng pointed out that a potential advantage to AVR-001 versus J&J’s Icotyde is that Avere’s IL-23 antagonist can be dosed weekly instead of daily.
Scrip - July 14, 2026
Internal Medicine Specialists Group Suggests Tracking Supplement Use Like Prescription Drugs
American College of Physicians study notes that “only one quarter” of the nearly 60% of US consumers older than 20 who report using supplements in the past 30 days “consume supplements that have been recommended by a health care professional.”
HBW Insight - July 14, 2026
American College of Physicians study notes that “only one quarter” of the nearly 60% of US consumers older than 20 who report using supplements in the past 30 days “consume supplements that have been recommended by a health care professional.”
HBW Insight - July 14, 2026
Whoop And Kinomatic Partner On Joint Replacement Recovery Pilot Targeting Opioid Reduction
Kinomatic and Whoop have launched a 12-week pilot to test whether continuous wearable monitoring can improve post-op outcomes and reduce opioid use in knee and hip replacement patients across three California clinics.
Medtech Insight - July 14, 2026
Kinomatic and Whoop have launched a 12-week pilot to test whether continuous wearable monitoring can improve post-op outcomes and reduce opioid use in knee and hip replacement patients across three California clinics.
Medtech Insight - July 14, 2026
Walmart Agrees To Police Mercury Content In Skin Lighteners Under NGO Settlement
Walmart Inc. agrees to monitor and remove skin lightening products with mercury above trace levels under a settlement with the Mercury Policy Project, in addition to paying more than $1m in penalties.
HBW Insight - July 14, 2026
Walmart Inc. agrees to monitor and remove skin lightening products with mercury above trace levels under a settlement with the Mercury Policy Project, in addition to paying more than $1m in penalties.
HBW Insight - July 14, 2026
What Industry Can Learn From The CAR-T Commercialization Playbook
Kite Pharmaceuticals' CAR-T therapy Yescarta met its internal launch forecast yet is widely perceived as a commercial underperformer. Two industry experts who lived through the launch explain what the gap between checkers-level and chess-level commercial strategy still means for the industry today.
In Vivo - July 14, 2026
Kite Pharmaceuticals' CAR-T therapy Yescarta met its internal launch forecast yet is widely perceived as a commercial underperformer. Two industry experts who lived through the launch explain what the gap between checkers-level and chess-level commercial strategy still means for the industry today.
In Vivo - July 14, 2026
US FDA Promotes Deputy To Acting Chief Information Officer
New Acting CIO Sanjay Kumar Sahoo is an agency veteran who helped consolidate the centers’ adverse event reporting systems.
Medtech Insight - July 14, 2026
New Acting CIO Sanjay Kumar Sahoo is an agency veteran who helped consolidate the centers’ adverse event reporting systems.
Medtech Insight - July 14, 2026
Claria Medical Wins De Novo Clearance Via STeP Pathway For Novel Contained Hysterectomy System
The US FDA has cleared Claria Medical's Claria System, a transvaginal hysterectomy device, via the STeP accelerated pathway. The company says the integrated device can remove a large uterus in an average of four minutes; full clinical trial data are expected later this year.
Medtech Insight - July 14, 2026
The US FDA has cleared Claria Medical's Claria System, a transvaginal hysterectomy device, via the STeP accelerated pathway. The company says the integrated device can remove a large uterus in an average of four minutes; full clinical trial data are expected later this year.
Medtech Insight - July 14, 2026
Sweden Bridges The Gap Between Prescription And OTC With New Category
Sweden will have a pharmacist-only medicines category from the start of 2027, opening up a new pathway for Rx-to-OTC reclassifications. Industry association Lif tells HBW Insight the reform could boost self-care access and draw investment, providing switch application rules are kept workable.
HBW Insight - July 14, 2026
Sweden will have a pharmacist-only medicines category from the start of 2027, opening up a new pathway for Rx-to-OTC reclassifications. Industry association Lif tells HBW Insight the reform could boost self-care access and draw investment, providing switch application rules are kept workable.
HBW Insight - July 14, 2026
Draig Raises $65m To Fund Depression Drug Candidate DT-101
With two Phase II studies underway for its lead depression candidate DT-101, Draig Therapeutics is looking to translate fresh financing into clinical milestones as competition in the major depressive disorder pipeline continues to evolve.
Scrip - July 14, 2026
With two Phase II studies underway for its lead depression candidate DT-101, Draig Therapeutics is looking to translate fresh financing into clinical milestones as competition in the major depressive disorder pipeline continues to evolve.
Scrip - July 14, 2026
FDA Flags Medtronic Harmony Catheter Recall As Class I Over Tip Detachment
The FDA has designated Medtronic's recall of the Harmony Delivery Catheter System as Class I after reports the catheter's distal tip can detach during implantation. The action spares the Harmony pulmonary valve itself.
Medtech Insight - July 14, 2026
The FDA has designated Medtronic's recall of the Harmony Delivery Catheter System as Class I after reports the catheter's distal tip can detach during implantation. The action spares the Harmony pulmonary valve itself.
Medtech Insight - July 14, 2026
GSK’s Jemperli Racks Up Registrational Trial Win In Rectal Cancer
Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.
Scrip - July 14, 2026
Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.
Scrip - July 14, 2026
Biogen’s Diranersen Efficacy Similar To Leqembi On Key Alzheimer’s Endpoint
The tau targeting Alzheimer’s therapy showed benefits across tau reduction and cognition endpoints in the Phase II CELIA trial detailed at AAIC, a first for the mechanism of action.
Scrip - July 14, 2026
The tau targeting Alzheimer’s therapy showed benefits across tau reduction and cognition endpoints in the Phase II CELIA trial detailed at AAIC, a first for the mechanism of action.
Scrip - July 14, 2026
Apotex Challenges Sandoz’s Infuvite With US Launch Of Generic Multivitamin Injections
Apotex enters the parenteral nutrition market by launching a generic version of the multivitamin injection Infuvite, boosted by a competitive generic therapy designation exclusivity.
Generics Bulletin - July 14, 2026
Apotex enters the parenteral nutrition market by launching a generic version of the multivitamin injection Infuvite, boosted by a competitive generic therapy designation exclusivity.
Generics Bulletin - July 14, 2026
Generic And Biosimilar Industry: Let Us Into US FDA National Priority Voucher Program
The generic drug lobbying group argued generics and biosimilars satisfy four of the FDA's five National Priority Voucher priorities.
Generics Bulletin - July 14, 2026
The generic drug lobbying group argued generics and biosimilars satisfy four of the FDA's five National Priority Voucher priorities.
Generics Bulletin - July 14, 2026
Natco Pharma Raises The Stakes Again, Taking 49% Share In Adcock Ingram
Indian multinational pharma company Natco Pharma has raised its stake in Adcock Ingram to 49%, in a $110m acquisition.
Generics Bulletin - July 14, 2026
Indian multinational pharma company Natco Pharma has raised its stake in Adcock Ingram to 49%, in a $110m acquisition.
Generics Bulletin - July 14, 2026
Spero Leverages Antibiotic Revenue To Bring In CD40L-Targeting Antibody From Innovent
Spero raised $105m, to be repaid by milestone fees and royalties from its newly approved, GSK-partnered antibiotic Utebzi. It will fund a Phase II trial in IgG4-related disease for SP001, in-licensed from Innovent.
Scrip - July 14, 2026
Spero raised $105m, to be repaid by milestone fees and royalties from its newly approved, GSK-partnered antibiotic Utebzi. It will fund a Phase II trial in IgG4-related disease for SP001, in-licensed from Innovent.
Scrip - July 14, 2026
Eisai, Biogen Push Full SC Leqembi With FDA Nod As Alzheimer’s Market Competition Builds
With Leqembi now offering a fully subcutaneous treatment pathway, attention turns to whether the expanded label can drive broader uptake in Alzheimer's disease.
Scrip - July 14, 2026
With Leqembi now offering a fully subcutaneous treatment pathway, attention turns to whether the expanded label can drive broader uptake in Alzheimer's disease.
Scrip - July 14, 2026
Over The Counter: The Dos And Don’ts Of Health Literacy, With Self-Care Forum’s Trevor Gore
HBW Insight speaks to Self-Care Forum trustee and behavioural scientist Trevor Gore about why treating health literacy as a readability exercise misses the real task of changing what people do about their health.
HBW Insight - July 14, 2026
HBW Insight speaks to Self-Care Forum trustee and behavioural scientist Trevor Gore about why treating health literacy as a readability exercise misses the real task of changing what people do about their health.
HBW Insight - July 14, 2026
A Pump Under Pressure: Fresenius Kabi’s Ivenix Keeps FDA Busy
A string of Class I recalls in two years, including a battery defect that appears to persist through its own fix, is turning Fresenius Kabi's Ivenix pump from a reliability-first disruptor into a mounting quality liability.
Medtech Insight - July 14, 2026
A string of Class I recalls in two years, including a battery defect that appears to persist through its own fix, is turning Fresenius Kabi's Ivenix pump from a reliability-first disruptor into a mounting quality liability.
Medtech Insight - July 14, 2026
When A Royalty Is Not Bankruptcy-Proof: Structuring Lessons from Mallinckrodt
Mallinckrodt's 2020 bankruptcy proved a synthetic royalty is only as safe as its structure. Absent a security interest or ownership stake, investors are just unsecured creditors facing discharge.
In Vivo - July 14, 2026
Mallinckrodt's 2020 bankruptcy proved a synthetic royalty is only as safe as its structure. Absent a security interest or ownership stake, investors are just unsecured creditors facing discharge.
In Vivo - July 14, 2026
AstraZeneca Snags Dizal’s Zegfrovy To Expand Into EGFR Exon20ins, PACC NSCLC
Deal Snapshot: AstraZeneca is acquiring global rights to Dizal’s Zegfrovy (sunvozertinib), an oral small molecule EGFR inhibitor for non-small cell lung cancer, for up to $1.5bn to extend its reach to the smaller subgroups of Exon20in and PACC mutations.
Scrip - July 14, 2026
Deal Snapshot: AstraZeneca is acquiring global rights to Dizal’s Zegfrovy (sunvozertinib), an oral small molecule EGFR inhibitor for non-small cell lung cancer, for up to $1.5bn to extend its reach to the smaller subgroups of Exon20in and PACC mutations.
Scrip - July 14, 2026
Alzheimer’s Blood Tests Equally Accurate In Primary, Secondary Care: Study
New data revealed at AAIC shows blood biomarkers proving their potential to diagnose Alzheimer’s in the sought-after primary care market – and may even have higher accuracy than other tests.
Medtech Insight - July 14, 2026
New data revealed at AAIC shows blood biomarkers proving their potential to diagnose Alzheimer’s in the sought-after primary care market – and may even have higher accuracy than other tests.
Medtech Insight - July 14, 2026
Federal Appeals Court Clears Plaintiffs’ Experts To Testify In OTC Acetaminophen Class Action
Circuit court decision returns to Southern New York District class action litigation alleging prenatal use of acetaminophen linked to autism and/or attention-deficit hyperactivity disorder in children, allowing testimony from three of six plaintiffs’ expert
HBW Insight - July 14, 2026
Circuit court decision returns to Southern New York District class action litigation alleging prenatal use of acetaminophen linked to autism and/or attention-deficit hyperactivity disorder in children, allowing testimony from three of six plaintiffs’ expert
HBW Insight - July 14, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Vertex’s Crinetics deal; AstraZeneca’s Phase III fail; J&J’s deal focus; Ipsen's search for rough diamonds; and Dyne’s CEO on strategy.
Scrip - July 14, 2026
In this week's episode: Vertex’s Crinetics deal; AstraZeneca’s Phase III fail; J&J’s deal focus; Ipsen's search for rough diamonds; and Dyne’s CEO on strategy.
Scrip - July 14, 2026
Consumers Will Push Back Against AI Reshape Of Beauty Marketing – Mintel
Consumer backlash against AI, demand for multisensory product experiences, and the rise of metabolic health will define the beauty industry through the end of the decade, says Mintel.
HBW Insight - July 14, 2026
Consumer backlash against AI, demand for multisensory product experiences, and the rise of metabolic health will define the beauty industry through the end of the decade, says Mintel.
HBW Insight - July 14, 2026
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis
In an interview, Avere CEO Andrew Cheng pointed out that a potential advantage to AVR-001 versus J&J’s Icotyde is that Avere’s IL-23 antagonist can be dosed weekly instead of daily.
Scrip - July 14, 2026
In an interview, Avere CEO Andrew Cheng pointed out that a potential advantage to AVR-001 versus J&J’s Icotyde is that Avere’s IL-23 antagonist can be dosed weekly instead of daily.
Scrip - July 14, 2026
Draig Raises $65m To Fund Depression Drug Candidate DT-101
With two Phase II studies underway for its lead depression candidate DT-101, Draig Therapeutics is looking to translate fresh financing into clinical milestones as competition in the major depressive disorder pipeline continues to evolve.
Scrip - July 14, 2026
With two Phase II studies underway for its lead depression candidate DT-101, Draig Therapeutics is looking to translate fresh financing into clinical milestones as competition in the major depressive disorder pipeline continues to evolve.
Scrip - July 14, 2026
GSK’s Jemperli Racks Up Registrational Trial Win In Rectal Cancer
Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.
Scrip - July 14, 2026
Another approval in a niche market will help the PD-1 immunotherapy hit its £2bn peak sales target.
Scrip - July 14, 2026
Biogen’s Diranersen Efficacy Similar To Leqembi On Key Alzheimer’s Endpoint
The tau targeting Alzheimer’s therapy showed benefits across tau reduction and cognition endpoints in the Phase II CELIA trial detailed at AAIC, a first for the mechanism of action.
Scrip - July 14, 2026
The tau targeting Alzheimer’s therapy showed benefits across tau reduction and cognition endpoints in the Phase II CELIA trial detailed at AAIC, a first for the mechanism of action.
Scrip - July 14, 2026
Spero Leverages Antibiotic Revenue To Bring In CD40L-Targeting Antibody From Innovent
Spero raised $105m, to be repaid by milestone fees and royalties from its newly approved, GSK-partnered antibiotic Utebzi. It will fund a Phase II trial in IgG4-related disease for SP001, in-licensed from Innovent.
Scrip - July 14, 2026
Spero raised $105m, to be repaid by milestone fees and royalties from its newly approved, GSK-partnered antibiotic Utebzi. It will fund a Phase II trial in IgG4-related disease for SP001, in-licensed from Innovent.
Scrip - July 14, 2026
Eisai, Biogen Push Full SC Leqembi With FDA Nod As Alzheimer’s Market Competition Builds
With Leqembi now offering a fully subcutaneous treatment pathway, attention turns to whether the expanded label can drive broader uptake in Alzheimer's disease.
Scrip - July 14, 2026
With Leqembi now offering a fully subcutaneous treatment pathway, attention turns to whether the expanded label can drive broader uptake in Alzheimer's disease.
Scrip - July 14, 2026
AstraZeneca Snags Dizal’s Zegfrovy To Expand Into EGFR Exon20ins, PACC NSCLC
Deal Snapshot: AstraZeneca is acquiring global rights to Dizal’s Zegfrovy (sunvozertinib), an oral small molecule EGFR inhibitor for non-small cell lung cancer, for up to $1.5bn to extend its reach to the smaller subgroups of Exon20in and PACC mutations.
Scrip - July 14, 2026
Deal Snapshot: AstraZeneca is acquiring global rights to Dizal’s Zegfrovy (sunvozertinib), an oral small molecule EGFR inhibitor for non-small cell lung cancer, for up to $1.5bn to extend its reach to the smaller subgroups of Exon20in and PACC mutations.
Scrip - July 14, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Vertex’s Crinetics deal; AstraZeneca’s Phase III fail; J&J’s deal focus; Ipsen's search for rough diamonds; and Dyne’s CEO on strategy.
Scrip - July 14, 2026
In this week's episode: Vertex’s Crinetics deal; AstraZeneca’s Phase III fail; J&J’s deal focus; Ipsen's search for rough diamonds; and Dyne’s CEO on strategy.
Scrip - July 14, 2026
Whoop And Kinomatic Partner On Joint Replacement Recovery Pilot Targeting Opioid Reduction
Kinomatic and Whoop have launched a 12-week pilot to test whether continuous wearable monitoring can improve post-op outcomes and reduce opioid use in knee and hip replacement patients across three California clinics.
Medtech Insight - July 14, 2026
Kinomatic and Whoop have launched a 12-week pilot to test whether continuous wearable monitoring can improve post-op outcomes and reduce opioid use in knee and hip replacement patients across three California clinics.
Medtech Insight - July 14, 2026
US FDA Promotes Deputy To Acting Chief Information Officer
New Acting CIO Sanjay Kumar Sahoo is an agency veteran who helped consolidate the centers’ adverse event reporting systems.
Medtech Insight - July 14, 2026
New Acting CIO Sanjay Kumar Sahoo is an agency veteran who helped consolidate the centers’ adverse event reporting systems.
Medtech Insight - July 14, 2026
Claria Medical Wins De Novo Clearance Via STeP Pathway For Novel Contained Hysterectomy System
The US FDA has cleared Claria Medical's Claria System, a transvaginal hysterectomy device, via the STeP accelerated pathway. The company says the integrated device can remove a large uterus in an average of four minutes; full clinical trial data are expected later this year.
Medtech Insight - July 14, 2026
The US FDA has cleared Claria Medical's Claria System, a transvaginal hysterectomy device, via the STeP accelerated pathway. The company says the integrated device can remove a large uterus in an average of four minutes; full clinical trial data are expected later this year.
Medtech Insight - July 14, 2026
FDA Flags Medtronic Harmony Catheter Recall As Class I Over Tip Detachment
The FDA has designated Medtronic's recall of the Harmony Delivery Catheter System as Class I after reports the catheter's distal tip can detach during implantation. The action spares the Harmony pulmonary valve itself.
Medtech Insight - July 14, 2026
The FDA has designated Medtronic's recall of the Harmony Delivery Catheter System as Class I after reports the catheter's distal tip can detach during implantation. The action spares the Harmony pulmonary valve itself.
Medtech Insight - July 14, 2026
A Pump Under Pressure: Fresenius Kabi’s Ivenix Keeps FDA Busy
A string of Class I recalls in two years, including a battery defect that appears to persist through its own fix, is turning Fresenius Kabi's Ivenix pump from a reliability-first disruptor into a mounting quality liability.
Medtech Insight - July 14, 2026
A string of Class I recalls in two years, including a battery defect that appears to persist through its own fix, is turning Fresenius Kabi's Ivenix pump from a reliability-first disruptor into a mounting quality liability.
Medtech Insight - July 14, 2026
Alzheimer’s Blood Tests Equally Accurate In Primary, Secondary Care: Study
New data revealed at AAIC shows blood biomarkers proving their potential to diagnose Alzheimer’s in the sought-after primary care market – and may even have higher accuracy than other tests.
Medtech Insight - July 14, 2026
New data revealed at AAIC shows blood biomarkers proving their potential to diagnose Alzheimer’s in the sought-after primary care market – and may even have higher accuracy than other tests.
Medtech Insight - July 14, 2026
Internal Medicine Specialists Group Suggests Tracking Supplement Use Like Prescription Drugs
American College of Physicians study notes that “only one quarter” of the nearly 60% of US consumers older than 20 who report using supplements in the past 30 days “consume supplements that have been recommended by a health care professional.”
HBW Insight - July 14, 2026
American College of Physicians study notes that “only one quarter” of the nearly 60% of US consumers older than 20 who report using supplements in the past 30 days “consume supplements that have been recommended by a health care professional.”
HBW Insight - July 14, 2026
Walmart Agrees To Police Mercury Content In Skin Lighteners Under NGO Settlement
Walmart Inc. agrees to monitor and remove skin lightening products with mercury above trace levels under a settlement with the Mercury Policy Project, in addition to paying more than $1m in penalties.
HBW Insight - July 14, 2026
Walmart Inc. agrees to monitor and remove skin lightening products with mercury above trace levels under a settlement with the Mercury Policy Project, in addition to paying more than $1m in penalties.
HBW Insight - July 14, 2026
Sweden Bridges The Gap Between Prescription And OTC With New Category
Sweden will have a pharmacist-only medicines category from the start of 2027, opening up a new pathway for Rx-to-OTC reclassifications. Industry association Lif tells HBW Insight the reform could boost self-care access and draw investment, providing switch application rules are kept workable.
HBW Insight - July 14, 2026
Sweden will have a pharmacist-only medicines category from the start of 2027, opening up a new pathway for Rx-to-OTC reclassifications. Industry association Lif tells HBW Insight the reform could boost self-care access and draw investment, providing switch application rules are kept workable.
HBW Insight - July 14, 2026
Over The Counter: The Dos And Don’ts Of Health Literacy, With Self-Care Forum’s Trevor Gore
HBW Insight speaks to Self-Care Forum trustee and behavioural scientist Trevor Gore about why treating health literacy as a readability exercise misses the real task of changing what people do about their health.
HBW Insight - July 14, 2026
HBW Insight speaks to Self-Care Forum trustee and behavioural scientist Trevor Gore about why treating health literacy as a readability exercise misses the real task of changing what people do about their health.
HBW Insight - July 14, 2026
Federal Appeals Court Clears Plaintiffs’ Experts To Testify In OTC Acetaminophen Class Action
Circuit court decision returns to Southern New York District class action litigation alleging prenatal use of acetaminophen linked to autism and/or attention-deficit hyperactivity disorder in children, allowing testimony from three of six plaintiffs’ expert
HBW Insight - July 14, 2026
Circuit court decision returns to Southern New York District class action litigation alleging prenatal use of acetaminophen linked to autism and/or attention-deficit hyperactivity disorder in children, allowing testimony from three of six plaintiffs’ expert
HBW Insight - July 14, 2026
Consumers Will Push Back Against AI Reshape Of Beauty Marketing – Mintel
Consumer backlash against AI, demand for multisensory product experiences, and the rise of metabolic health will define the beauty industry through the end of the decade, says Mintel.
HBW Insight - July 14, 2026
Consumer backlash against AI, demand for multisensory product experiences, and the rise of metabolic health will define the beauty industry through the end of the decade, says Mintel.
HBW Insight - July 14, 2026
Apotex Challenges Sandoz’s Infuvite With US Launch Of Generic Multivitamin Injections
Apotex enters the parenteral nutrition market by launching a generic version of the multivitamin injection Infuvite, boosted by a competitive generic therapy designation exclusivity.
Generics Bulletin - July 14, 2026
Apotex enters the parenteral nutrition market by launching a generic version of the multivitamin injection Infuvite, boosted by a competitive generic therapy designation exclusivity.
Generics Bulletin - July 14, 2026
Generic And Biosimilar Industry: Let Us Into US FDA National Priority Voucher Program
The generic drug lobbying group argued generics and biosimilars satisfy four of the FDA's five National Priority Voucher priorities.
Generics Bulletin - July 14, 2026
The generic drug lobbying group argued generics and biosimilars satisfy four of the FDA's five National Priority Voucher priorities.
Generics Bulletin - July 14, 2026
Natco Pharma Raises The Stakes Again, Taking 49% Share In Adcock Ingram
Indian multinational pharma company Natco Pharma has raised its stake in Adcock Ingram to 49%, in a $110m acquisition.
Generics Bulletin - July 14, 2026
Indian multinational pharma company Natco Pharma has raised its stake in Adcock Ingram to 49%, in a $110m acquisition.
Generics Bulletin - July 14, 2026
What Industry Can Learn From The CAR-T Commercialization Playbook
Kite Pharmaceuticals' CAR-T therapy Yescarta met its internal launch forecast yet is widely perceived as a commercial underperformer. Two industry experts who lived through the launch explain what the gap between checkers-level and chess-level commercial strategy still means for the industry today.
In Vivo - July 14, 2026
Kite Pharmaceuticals' CAR-T therapy Yescarta met its internal launch forecast yet is widely perceived as a commercial underperformer. Two industry experts who lived through the launch explain what the gap between checkers-level and chess-level commercial strategy still means for the industry today.
In Vivo - July 14, 2026
When A Royalty Is Not Bankruptcy-Proof: Structuring Lessons from Mallinckrodt
Mallinckrodt's 2020 bankruptcy proved a synthetic royalty is only as safe as its structure. Absent a security interest or ownership stake, investors are just unsecured creditors facing discharge.
In Vivo - July 14, 2026
Mallinckrodt's 2020 bankruptcy proved a synthetic royalty is only as safe as its structure. Absent a security interest or ownership stake, investors are just unsecured creditors facing discharge.
In Vivo - July 14, 2026